skip to content

Faculty of MedicineCenter for Biochemistry

Publications

⇒ all publications

Selected recent publications

  1. Montinaro A, Areso Zubiaur I, Saggau J, Kretz AL, Ferreira RMM, Hassan O, Kitzig E, Müller I, El-Bahrawy MA, von Karstedt S, Kulms D, Liccardi G, Lemke J, Walczak H. Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers. Cell Death and Differentiation, 29(3):492-503, 2022.
  2. von Karstedt S, Walczak H. An unexpected turn of fortune: targeting TRAIL-Rs in KRAS-driven cancer. Cell Death and Discovery, 6: 14. eCollection, 2020.
  3. Annibaldi A, Walczak H. Death Receptors and Their Ligands in Inflammatory Disease and Cancer. Cold Spring Harbor Perspectives in Biology, 12(9):a036384, 2020.
  4. Peltzer N, Walczak H. Cell Death and Inflammation - A Vital but Dangerous Liaison. Trends in Immunology 40: 387-402, 2019.
  5. Peltzer N, Darding M, Montinaro A, Draber P, Draberova H, Kupka S, Rieser E, Fisher A, Hutchinson C, Taraborrelli L, Hartwig T, Lafont E, Haas TL, Shimizu Y, Böiers C, Sarr A, Rickard J, Alvarez-Diaz S, Ashworth MT, Beal A, Enver T, Bertin J, Kaiser W, Strasser A, Silke J, Bouillet P, Walczak H. LUBAC is essential for embryogenesis by preventing cell death and enabling haematopoiesis. Nature, 557: 112-117, 2018.  
  6. Lafont E, Draber P, Rieser E, Reichert M, Kupka S, de Miguel D, Draberova H, von Mässenhausen A, Bhamra A, Henderson S, Wojdyla K, Chalk A, Surinova S, Linkermann A, Walczak H. TBK1 and IKKε prevent TNF-induced cell death by RIPK1 phosphorylation. Nature Cell Biology, 20: 1389-1399, 2018.
  7. Taraborrelli L, Peltzer N, Montinaro A, Kupka S, Rieser E, Hartwig T, Sarr A, Darding M, Draber P, Haas TL, Akarca A, Marafioti T, Pasparakis M, Bertin J, Gough PJ, Bouillet P, Strasser A, Leverkus M, Silke J, Walczak H. LUBAC prevents lethal dermatitis by inhibiting cell death induced by TNF, TRAIL and CD95L. Nature Communications, 9: 3910, 2018.
  8. von Karstedt S, Montinaro A, Walczak H. Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy. Nature Reviews Cancer, 17: 352-366, 2017.
  9. Zinngrebe J, Rieser E, Taraborrelli L, Peltzer N, Hartwig T, Ren H, Kovács I, Endres C, Draber P, Darding M, von Karstedt S, Lemke J, Dome B, Bergmann M, Ferguson BJ, Walczak H. LUBAC deficiency perturbs TLR3 signaling to cause immunodeficiency and autoinflammation. Journal of Experimental Medicine, 213: 2671-2689, 2016.
  10. von Karstedt S, Conti A, Nobis M, Montinaro A, Hartwig T, Lemke J, Legler K, Annewanter F, Campbell AD, Taraborrelli L, Grosse-Wilde A, Coy JF, El-Bahrawy MA, Bergmann F, Koschny R, Werner J, Ganten TM, Schweiger T, Hoetzenecker K, Kenessey I, Hegedüs B, Bergmann M, Hauser C, Egberts JH, Becker T, Röcken C, Kalthoff H, Trauzold A, Anderson KI, Sansom OJ, Walczak H. Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis. Cancer Cell, 27(4):561-73., 2015.
  11. Draber P, Kupka S, Reichert M, Draberova H, Lafont E, de Miguel D, Spilgies L, Surinova S, Taraborrelli L, Hartwig T, Rieser E, Martino L, Rittinger K, Walczak H. LUBAC-recruited CYLD and A20 restrict gene activation and regulate cell death by exerting opposing effects on linear ubiquitin in signaling complexes. Cell Reports, 13, 2258-2272, 2015.

Additional selected publications

  1. Shimizu, Y., Peltzer, N., Sevko, A., Lafont, E., Sarr, A., Draberova, H., Walczak H. The linear ubiquitin chain assembly complex acts as a liver tumor suppressor and inhibits hepatocyte apoptosis and hepatitis. Hepatology, 65: 1963-1978, 2017.
  2. Lafont, E., Kantari-Mimoun, C., Draber, P., De Miguel, D., Hartwig, T., Reichert, M., Kupka, S., Shimizu, Y., Taraborrelli, L., Spit, M., Sprick, M.R., Walczak, H. The linear ubiquitin chain assembly complex regulates TRAIL-induced gene activation and cell death EMBO Journal, 36: 1147-1166, 2017.
  3. Hartwig, T., Montinaro, A., von Karstedt, S., Sevko, A., Surinova, S., Chakravarthy, A., Taraborrelli, L., Draber, P., Lafont, E., Arce Vargas, F., El-Bahrawy, M.A., Quezada, S.A., Walczak, H. The TRAIL-Induced cancer secretome promotes a tumor-supportive immune microenvironment via CCR2. Molecular Cell 65: 730-742, 2017.
  4. Kupka, S., De Miguel, D., Draber, P., Martino, L., Surinova, S., Rittinger, K., Walczak H. SPATA2-Mediated Binding of CYLD to HOIP Enables CYLD Recruitment to Signaling Complexes. Cell Reports 16: 2271-2280, 2016.
  5. Peltzer, N., Rieser, E., Taraborrelli, L., Draber, P., Darding, M., Pernaute, B., Shimizu, Y., Daboh, A., Draberova, H., Montinaro, A., Martinez-Barbera, J.P., Silke, J., Rodriguez, T.A. and Walczak, H. HOIP deficiency caused embryonic lethality by aberrant TNFR1-mediated endothelial cell death. Cell Reports 9: 153-165, 2014.                  
  6. Gerlach, B., Cordier, S.M., Schmukle, A.C., Emmerich, C.H., Rieser, E., Haas, T.L., Webb, A.I., Rickard, J.A., Anderton, H., Wong, W.W.-L., Nachbur, U., Gangoda, L., Warnken, U., Purcell, A.W., Silke, J., Walczak, H. Linear ubiquitination prevents inflammation and regulates immune signalling. Nature 471: 591- 6. 2011.
  7. Tuthill, M., Montinaro, A., Zinngrebe, J., Prieske, K., Draber, P., Prieske, S., Newsom-Davis, T., von   Karstedt, S., Graves, J. and Walczak, H. TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill. Oncogene. 34:2138-44. 2014.  
  8. Lemke, J., von Karstedt, S., Abd El Hay, M., Conti, A., Arce, F., Montinaro, A., Papenfuss, K., El-Bahrawy, M. A. and Walczak, H. Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFLIP and Mcl-1. Cell Death Differentiation 21: 491-502, 2014.
  9. Gerlach, B., Cordier, S.M., Schmukle, A.C., Emmerich, C.H., Rieser, E., Haas, T.L., Webb, A.I., Rickard, J.A., Anderton, H., Wong, W.W.-L., Nachbur, U., Gangoda, L., Warnken, U., Purcell, A.W., Silke, J., Walczak, H. Linear ubiquitination prevents inflammation and regulates immune signalling. Nature 471: 591- 596, 2011.
  10. Haas, T.L., Emmerich, C.H., Gerlach, B., Schmukle, A.C., Cordier., S.M., Rieser, E., Feltham, R., Vince, J., Warnken, U., Wenger, T., Koschny, R., Komander, D., Silke, J., Walczak, H. Recruitment of the linear ubiquitin chain assembly complex (LUBAC) stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Molecular Cell 36: 831-844, 2009.
  11. Grosse-Wilde, A., Voloshanenko, O., Bailey, S.L., Longton, G.M., Schaefer, U., Csernok, A.I.,Schütz, G., Greiner, E.F., Kemp, C.J., Walczak H. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. Journal of Clinical Investigation 118: 100-110, 2008.
  12. Koschny, R., Ganten, T.M., Sykora, J., Haas, T.L., Sprick, M.R., Kolb, A., Stremmel, W., Walczak, H. TRAIL/Bortezomib co-treatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology 45: 649-658, 2007.
  13. Koschny, R., Holland, H., Sykora, J., Haas, T.L., Sprick, M.R., Ganten, T.M., Krupp, W., Bauer, M., Ahnert, P., Meixensberger, J., Walczak, H. Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clinical Cancer Research 13: 3403-3412, 2007.
  14. Ganten, T.M., Koschny, R., Sykora, J., Schulze-Bergkamen, H., Büchler, P., Haas T.L., Schader, M.B., Untergasser A., Stremmel, W., Walczak, H. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clinical Cancer Research, 12: 2640-2646, 2006.
  15. Ganten, T.M., Koschny, R., Haas, T.L., Sykora, J., Li-Weber, M., Herzer, K., Walczak, H. Proteasome inhibition sensitizes hepatocellular carcinoma cells but not primary human hepatocytes for TRAIL-induced apoptosis independently of NF-B. Hepatology 42: 588-597, 2005.
  16. Ganten T.M., Haas T.L., Sykora J., Stahl H., Sprick M.R., Fas S.C., Krueger A., Weigand M.A., Grosse-Wilde A., Stremmel W., Krammer P.H., Walczak H. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death and Differentiation 11 Supp 1: 86-96, 2004.                    
  17. Leverkus, M., Sprick, M.R., Wachter, T., Mengling, T., Baumann, B., Serfling, E., Bröcker, E.-B., Goebeler, M., Neumann, M., Walczak, H. Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation. Molecular and Cellular Biology 23: 777-790, 2003. Washburn, B., Weigand, M.A., Grosse-Wilde, A., Janke, M., Stahl, H., Rieser, E., Sprick, M.R., Schirrmacher, V., Walczak, H.  TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle Disease Virus.  Journal of Immunology 170: 1814-1821, 2003.
  18. Sprick, M., Rieser, E., Stahl, H., Grosse-Wilde, A., Weigand, M.A., Walczak, H.  Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but cannot functionally substitute caspase-8.  EMBO Journal 21: 4520-30, 2002.       
  19. Sprick, M.R., Weigand, M.A., Rieser, E., Rauch C.T., Juo, P., Blenis, J., Krammer, P.H. Walczak, H.  FADD/MORT1 and Caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2.  Immunity 12: 599-609, 2000.
  20. Walczak, H., Bouchon, A., Stahl, H., Krammer P.H. TRAIL retains its apoptosis-inducing capacity on Bcl-2-or Bcl-xL-overexpressing chemotherapy-resistant tumor cells. Cancer Research 60: 3051-3057, 2000.  
  21. Walczak, H., Miller, R.E., Ariail, K., Gliniak, B., Griffith, T.S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., Smith, C., Smolak, P., Goodwin, R.G., Rauch, C.T., Schuh, J.C.L., Lynch, D.H. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nature Medicine 5: 157-163, 1999.    
  22. Walczak, H., Degli-Esposti, M.A., Johnson, R.S., Smolak, P.J., Waugh, J.Y., Boiani, N., Timour, M.S., Gerhart, M.J., Schooley, K.A., Smith, C.A., Goodwin, R.G., Rauch, C.T. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.  EMBO Journal 16: 5386-5397, 1997.
  23. *Dhein, J., *Walczak, H., Bäumler, C., Debatin, K.M., Krammer, P.H.  Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373: 438-41, 1995.